Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022
Research

Overseas Treatment of Latent Tuberculosis Infection in US–Bound Immigrants

Amera KhanComments to Author , Christina R. Phares, Hoang Lan Phuong, Dang Thi Kieu Trinh, Ha Phan, Cindy Merrifield, Phan Thi Hong Le, Quach Thi Kim Lien, Sooc Ngoc Lan, Phan Thi Kim Thoa, Le Tran Minh Thu, Tiffany Tran, Cuc Tran, Lucy Platt, Susan A. Maloney, Nguyen Viet Nhung, Payam Nahid, and John E. Oeltmann
Author affiliations: Stop TB Partnership, Geneva, Switzerland (A. Khan); London School of Hygiene and Tropical Medicine, London, UK (A. Khan, L. Platt); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.R. Phares, C. Tran, S.A. Maloney, J.E. Oeltmann); Cho Ray Hospital Visa Medical Clinic, Ho Chi Minh City, Vietnam (H.L. Phuong, D.T.K. Trinh, P.T.H. Le, Q.T.K. Lien, S.N. Lan, P.T.K. Thoa, L.T.M. Thu); Vietnam National TB Program/University of California–San Francisco Research Collaboration, Hanoi, Vietnam (H. Phan, C. Merrifield, T. Tran, N.V. Nhung, P. Nahid); University of California–San Francisco, San Francisco, California, USA (H. Phan, C. Merrifield, P. Nahid); Vietnam National TB Program, Hanoi (N.V. Nhung)

Main Article

Table 1

Characteristics of study participants in the Preventing Tuberculosis Overseas Pilot Study of US immigrant visa applicants, Vietnam, 2018–2019*

Characteristic No. (%) participants
Recruited Enrolled IGRA
processed		 IGRA-positive 3HP-eligible Initiated 3HP Completed 3HP
Total
 5,311
 2,438
 2,276
 484
 452
 304
 268
Sex
F 2,888 (54) 1,350 (55) 1,304 (57) 272 (56) 259 (57) 170 (56) 152 (57)
M
 2,423 (46)
 1,088 (45)
 972 (43)
 212 (44)
 193 (43)
 134 (44)
 116 (43)
Age group, y
12–14 298 (6) 143 (6) 142 (6)† 9 (2) 9 (2) 4 (1) 4 (1)
15–17 431 (8) 226 (9) 223 (10) 19 (4) 18 (4) 14 (5) 13 (5)
18–35 1,527 (29) 773 (32) 749 (33) 114 (24) 109 (24) 69 (23) 62 (23)
36–65 2,909 (55) 1,254 (51) 1,128 (50) 333 (69) 307 (68) 211 (69) 184 (69)
≥66 146 (3) 42 (2) 34 (1) 9 (2) 9 (2) 6 (2) 5 (2)

*IGRA, interferon-γ release assay; 3HP, 3-mo regimen of isoniazid and rifapentine.
†IGRA required as part of medical examination for participants 12–14 y of age; 1 participant’s IGRA was not processed for the study because of recent measles, mumps, and rubella vaccination.

Main Article

Page created: December 13, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external